Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease

British Journal of Cancer

Volumn 100, Issue 10, 2009, Pages 1534-1539

  Mayor, R ^a,b   Casadome L ^c   Azuara, D ^c   Moreno, V ^c   Clark, S J ^d   Capella G ^c   Peinado, M A ^a,b,e  

^a Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e Institut de Medicina Predictiva i Personalitzada del Cancer IMPPC   (Spain)

Author keywords

Colorectal cancer; CpG island hypermethylation; Diagnostic marker; DNA methylation; Epigenetic silencing; Gene silencing; Prognostic marker

Indexed keywords

DNA;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 2Q; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC VALUE; DISEASE MARKER; DNA DETERMINATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL RATE; SURVIVAL TIME;

ADENOMA; CARCINOMA; CHROMOSOMES, HUMAN, PAIR 2; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FECES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; INHIBIN-BETA SUBUNITS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349175004     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605045     Document Type: Article

References (42)

1. Ahlquist DA (2002) Stool-based DNA tests for colorectal cancer: clinical potential and early results. Rev Gastroenterol Disord 2(Suppl 1): S20-S26
2. Bachar-Dahan L, Goltzmann J, Yaniv A, Gazit A (2006) Engrailed-1 negatively regulates beta-catenin transcriptional activity by destabilizing beta-catenin via a glycogen synthase kinase-3beta-independent pathway. Mol Biol Cell 17: 2572-2580
3. Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1): S4-S11
4. Belshaw NJ, Elliott GO, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT (2004) Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev 13: 1495-1501
5. Brenner DE, Rennert G (2005) Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst 97: 1107-1109
6. Capeila G (2005) Is fecal DNA testing superior to fecal occult-blood testing for colorectal cancer screening? Nat Clin Pract Oncol 2: 234-235
7. Castells A, Puig P, Mora J, Boadas J, Boix L, Urgell E, Sole M, Capeila G, Lluis F, Fernandez-Cruz L, Navarro S, Farre A (1999) K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 17: 578-584
8. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97: 1124-1132
9. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D'Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J (2001) Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93: 858-865
10. Esteller M (2007a) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286 - 298
11. Esteller M (2007b) Epigenetic gene silencing in cancer: the DNA hyper -methylome. Hum Mol Genet 16(Spec No 1): R50-R59
12. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153
13. Frigola J, Sole X, Paz MF, Moreno V, Esteller M, Capeila G, Peinado MA (2005) Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 14: 319-326
14. Frigola J, Song J, Stirzaker C, Hinsheiwood RA, Peinado MA, Clark S (2006) Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38: 540-549
15. Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello E, Benasco C, Campos O, Capeila G, Peinado MA (2000) Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 92: 544-549
16. Hesson LB, Cooper WN, Latif F (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26: 7283-7301
17. Hitchins MP, Lin VA, Buckle A, Cheong K, Halani N, Ku S, Kwok CT, Packham D, Suter CM, Meagher A, Stirzaker C, Clark S, Hawkins NJ, Ward RL (2007) Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res 67: 9107-9116
18. Huang Z, Li L, Wang J (2007a) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52: 2287-2291
19. Huang ZH, Li LH, Yang F, Wang JF (2007b) Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 13: 950-954
20. Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N (2008) The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 6: 585-591
21. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253 - 266
22. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Goke B, Lamerz R, Kolligs FT (2005) Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 3: 142 - 149
23. Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Lee JF, Sung JJ (2004) Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem 50: 2179-2182
24. Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ (2005) Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 100: 2274-2279
25. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grutzmann R, Pilarsky C, Sledziewski A (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54: 414-423
26. Melki JR, Vincent PC, Clark SJ (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59: 3730-3740
27. Mutskov V, Felsenfeld G (2004) Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 23: 138-149
28. Nakayama G, Hibi K, Kodera Y, Koike M, Fujiwara M, Nakao A (2007) P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma. Anticancer Res 27: 3367-3370
29. Pefko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM (2005) Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 11: 1203-1209
30. Puig P, Urgell E, Capella G, Villanueva A, Grau M, Sancho FJ, Pujol J, Lluis F, Gonzalez-Sastre F, Mora J (1999) Improved detection of K-ras codon 12 mutations in fecal exfoliated cells. Lab Invest 79: 617-618
31. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP (2007) Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 104: 5527-5532
32. Rodriguez J, Muñoz M, Vives L, Frangou CG, Groudine M, Peinado MA (2008) Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci USA 105: 19809-19814
33. Stirzaker C, Song JZ, Davidson B, Clark SJ (2004) Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64: 3871-3877
34. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, Graham A, Southgate J, Asselain B, Allory Y, Abbou CC, Albertson DG, Thiery JP, Chopin DK, Pinkel D, Radvanyi F (2006) Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38: 1386-1396
35. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R (2005) Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 25: 3923-3933
36. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686
37. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz Jr DJ, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B (2002) Detection of APC mutations in fecal DNA from patients with colorectal tumors.N Engl J Med 346: 311-320
38. Vendrell E, Morales C, Risques RA, Capella G, Peinado MA (2005) Genomic determinants of prognosis in colorectal cancer. Cancer Lett 221: 1-9
39. Vendrell E, Ribas M, Vails J, Sole X, Grau M, Moreno V, Capella G, Peinado MA (2007) Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. Int J Oncol 30: 1099-1107
40. Wang DR, Tang D (2008) Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 14: 524-531
41. Zitt M, Zitt M, Muller HM (2007) DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities? Dis Markers 23: 51-71
42. Zou HZ, Yu BM, Wang ZW, Sun JY, Cang H, Gao F, Li DH, Zhao R, Feng GG, Yi J (2002) Detection of aberrant pl6 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8: 188-191